# RNAimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rnaimmune

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.rnaimmune.com
- Total disclosed funding: $39M
- Latest round: Series A (Mar 29, 2022)
- Investors on record: 7

## About

RNAimmune, Inc. is a biotechnology company focused on creating mRNA-based therapeutics and vaccines designed to leverage the body's natural immune responses to tackle various diseases.Founded in 2020 and headquartered in Gaithersburg, US, RNAimmune, Inc. specializes in developing mRNA therapeutics and vaccines. The company has received Series A funding totaling USD 27.00 mn on March 29, 2022, with key investors including Sirnaomics, Inc., Smooth River Wealth Management, and Rotating Boulder Fund. The CEO, Dong Shen, has a background in biotechnology, although specific details about prior experience are not provided.RNAimmune specializes in innovative mRNA-based therapeutic solutions and vaccines, including personalized neoantigen vaccines for cancer, prophylactic vaccines for infectious diseases, and mRNA therapeutics targeting rare diseases. Utilizing proprietary mRNA technology, their advanced delivery systems, such as lipid nanoparticle (LNP) and polypeptide lipid nanoparticle (PLNP) formulations, effectively enhance immune responses. Their primary clients include pharmaceutical companies, biotechnology firms, research institutions, and healthcare providers in markets like the United States and China.RNAimmune generates revenue through strategic partnerships, licensing agreements, and collaborations with pharmaceutical companies and research institutions. They have successfully licensed their RSV mRNA vaccine technology to Hualan Biological Vaccine Inc. and are involved in partnerships aimed at developing various vaccines and therapeutics. Revenue models typically include milestone-based payments tied to clinical trial progress, allowing for funding of ongoing research and development initiatives.With the recent Series A funding of USD 27.00 mn, secured in March 2022, RNAimmune plans to scale its team and advance its mRNA vaccine programs. The investment will enhance their ability to develop upcoming products, including new mRNA vaccines and therapeutics. The company is focused on expanding into new markets, particularly in regions like Europe and Asia, aiming for broader global reach by 2024.

## Funding rounds

- Series A, Mar 29, 2022, $27M — Rotating Boulder Fund, Sirnaomics, Inc., Smooth River Wealth Management
- Seed, Apr 21, 2021, $10M — Terra Magnum Capital Partners, Hongrun Capital, Highforest Capital, Smooth River Wealth Management, Shanghai Walga Biotechnology
- Seed, Aug 24, 2020, $2.4M — Terra Magnum Capital Partners

## Investors

- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Seed
- Hongrun Capital — Seed
- Highforest Capital — Seed
- Smooth River Wealth Management — Seed, Series A
- Shanghai Walga Biotechnology — Seed
- Rotating Boulder Fund (https://capitalatlas.ai/funds/rotating-boulder-fund) — Series A
- Sirnaomics, Inc. — Series A